ArticleCommunications medicine2022

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.

Rodney P Rocconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.